Series B traction ShiraTronics recently closed a $66M Series B financing, signaling strong investor confidence and a healthy runway to scale commercial activities, clinical support, and market entry efforts in chronic migraine therapies.

Clinical-stage momentum The company is advancing a Chronic Migraine System with ongoing clinical trials and a pilot Australian study, presenting clear near-term opportunities to engage with key opinion leaders, research centers, and potential early adopters.

Global expansion With international pilot activity and upcoming trial procedures, there is potential to pursue regional distributor partnerships, hospital networks, and patient access programs across multiple geographies.

Strategic leadership Leadership changes and experienced medical device governance imply a proactive approach to commercialization, enabling targeted outreach to strategic accounts, group purchasing organizations, and clinical partners.

Financial health A multi-million funding history, combined with ongoing clinical development, suggests capacity for collaboration on trials, co-development projects, and payer engagement initiatives to support reimbursement pathways.